Wound complications following rivaroxaban administration: A multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty

Journal of Bone and Joint Surgery

Volumn 94, Issue 17, 2012, Pages 1554-1558

  Jameson, Simon S ^a   Rymaszewska, Monika ^a   James, Philip ^b   Serrano Pedraza, Ignacio ^c   Muller, Scott D ^d   Hui, Anthony C W ^a   Reed, Mike R ^d  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b CHKS Healthcare Intelligence Services   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d NORTHUMBRIA HEALTHCARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

AGED; ARTICLE; BRAIN HEMORRHAGE; DEEP VEIN THROMBOSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIP ARTHROPLASTY; HOSPITAL READMISSION; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REOPERATION; SURGICAL INFECTION; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; WOUND COMPLICATION;

EID: 84866623327     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.K.00521     Document Type: Article

References (27)

1. NHS. Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 170. http://www.nice.org.uk/nicemedia/live/12133/43811/43811.pdf. Accessed 2011 Jan19.
2. NHS. Venous thromboembolism: reducing the risk. NICE clinical guideline 92. http://www.nice.org.uk/nicemedia/live/12695/47195/47195.pdf. Accessed 2011 Jan 19.
3. Health Canada. Summary basis of decision (SBD) Prxarelto. Submission control number 119111. http://www.hc-sc.gc.ca/dhp-mps/alt-formats/hpfb-dgpsa/ pdf/prodpharma/sbd-smd-2009-xarelto-119111-eng.pdf. Accessed 2011 Jan 19.
4. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75. (Pubitemid 351930851)
5. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24.
6. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86. (Pubitemid 351930852)
7. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. Epub 2009 May 4.
8. Duggan ST, Scott LJ, Plosker GL. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery. Drugs. 2009;69(13):1829-51. doi: 10.2165/11200890-000000000-00000.
9. National Institute for Health and Clinical Excellence. http://www.nice.org.uk/. Accessed 2011 Jan 16.
10. Trkulja V, Kolundzic R. Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials. Croat Med J. 2010 Apr;51(2):113-23.
11. Lotke PA. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008;359:2174.
12. Jensen CD, Steval A, Partington PF, Reed MR, Muller SD. Return to theatre following total hip and knee replacement, before and after the introduction of rivaroxaban: a retrospective cohort study. J Bone Joint Surg Br. 2011 Jan;93(1):91-5.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. (Pubitemid 17055592)
14. Zar JH. Biostatistical analysis. 5th ed. London: Prentice Hall Int; 2010.
15. Fleiss B, Levin JL, Paik MC. Statistical methods for rates and proportions. 3rd ed. New York: John Wiley & Sons; 2003.
16. Bland JM, Altman DG. Statistics notes. The odds ratio. BMJ. 2000 May 27; 320(7247):1468. (Pubitemid 30311684)
17. Moser BK, Stevens GR, Watts CL. The two-sample t-test versus Satterthwaite's approximate F test. Commun Stat Theory Methodol. 1989;18(11):3963-75.
18. Ruxton GD. The unequal variance t-test is an underused alternative to Student's t-test and the Mann-Whitney U test. Behav Ecol. 2006 Jul-Aug;17(4):688-90. (Pubitemid 43992440)
19. Samama MM. The mechanism of action of rivaroxaban - an oral, direct Factor Xa inhibitor - compared with other anticoagulants. Thromb Res. 2011 Jun;127(6): 497-504. Epub 2010 Oct 2.
20. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br. 2009 May;91(5):636-44.
21. Galat DD, McGovern SC, Larson DR, Harrington JR, Hanssen AD, Clarke HD. Surgical treatment of early wound complications following primary total knee arthroplasty. J Bone Joint Surg Am. 2009;91(1):48-54.
22. Galat DD, McGovern SC, Hanssen AD, Larson DR, Harrington JR, Clarke HD. Early return to surgery for evacuation of a postoperative hematoma after primary total knee arthroplasty. J Bone Joint Surg Am. 2008;90(11):2331-6.
23. Johnson & Johnson Pharmaceutical Research & Development. Advisory Committee briefing book. Rivaroxaban for the prophylaxis of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery. http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ UCM138385. Accessed 2011 Jan 19.
24. Jones R. Limitations of the HRG tariff: excess bed days. Br J Healthcare Manag. 2008;14(8):354-5.
25. Muller SD, Khaw FM, Morris R, Crozier AE, Gregg PJ. Ulceration of the lower leg after total knee replacement a five-year review. J Bone Joint Surg Br. 2001 Nov;83(8):1116-8. (Pubitemid 33138676)
26. Cordell-Smith JA, Williams SC, Harper WM, Gregg PJ. Lower limb arthroplasty complicated by deep venous thrombosis. Prevalence and subjective outcome. J Bone Joint Surg Br. 2004 Jan;86(1):99-101. (Pubitemid 38128714)
27. Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J. Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med. 2000 Mar 13;160(5):669-72. (Pubitemid 30140416)